1.57 USD
↗ 0.09 (5.77%)PRE MARKET (AS OF 04:01 AM EDT)
IN8bio, Inc. Common Stock
INABNASDAQ • USD
Market: OPEN
Open?$1.65
High?$1.65
Low?$1.65
Prev. Close?$1.56
Volume?6
Avg. Volume?79.1K
VWAP?$1.65
Rel. Volume?0.00x
Bid / Ask
Bid?$1.52 × 100
Ask?$1.57 × 100
Spread?$0.05
Midpoint?$1.55
Valuation & Ratios
Market Cap?15.4M
Shares Out?9.8M
Float?7.0M
Float %?70.7%
P/E Ratio?N/A
P/B Ratio?0.56
EPS?-$1.97
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?8.82Strong
Quick Ratio?8.82Strong
Cash Ratio?8.57Strong
Debt/Equity?0.01Low
ValuationATTRACTIVELY VALUED
Score100/100
P/E?N/A▾
P/B?0.56CHEAP▾
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?0.6CHEAP▾
EV/Sales?N/A▾
Returns & Efficiency
ROE?-70.5%WEAK▾
ROA?-60.2%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$-11435541
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
Employees
17
Market Cap
14.8M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2021-07-30
Address
EMPIRE STATE BUILDING
NEW YORK, NY 10118
Phone: (646) 600-6438
NEW YORK, NY 10118
Phone: (646) 600-6438